Nature of Business and Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended		9 Months Ended	12 Months Ended
	Apr. 06, 2021	Nov. 09, 2020	Mar. 12, 2020	Apr. 12, 2019	Apr. 02, 2018	Mar. 31, 2022	Nov. 09, 2020	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Conversion of convertible preferred stock into common stock upon initial public offering, Shares					24,168,656
Payments of Stock Issuance Costs								$ 100
Proceeds through future financings								$ 148,400
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs									$ 49,744
Net loss									95,764	128,694
Accumulated deficit									424,132	$ 328,368
Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds through future financings			$ 148,400
Oxford Biomedica plc
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from Sale of Equity Method Investments									50,000
Upfront Payment Received									$ 130,000
Oxford Biomedica plc | Subsequent Event [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from Sale of Equity Method Investments						$ 130,000
Initial Public Offering
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares					10,350,000
Common stock at a public offering price					$ 16.00
Net proceeds from initial public offering after underwriting discounts and commissions and offering expenses					$ 150,800
Follow On Offering | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares	6,596,306			5,555,556					6,596,306
Shares issued price per share	$ 7.58			$ 22.50
Net proceeds after deducting underwriting discounts and commissions and offering expenses	$ 49,700			$ 116,900
Common Stock Offering Expenses	$ 300
Underwriters Option | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares	989,445			833,333
Shares issued price per share	$ 7.58			$ 22.50
Net proceeds after deducting underwriting discounts and commissions and offering expenses				$ 17,600
ATM
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares								114,914
Shares issued price per share								$ 14.00
Commission Fee								3.00%
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs									$ 1,500
ATM | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds through future financings			$ 150,000
ATM | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares									114,914
ATM | Oxford Biomedica plc
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction									80.00%
ATM | Homology
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction									20.00%
Private Placement
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares		5,000,000					5,000,000
Shares issued price per share		$ 12.00					$ 12.00
Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs		$ 60,000					$ 60,000
Private Placement | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Shares										5,000,000